Edit |   |
---|---|
Antigenic Specificity | PDCD1/PD1/CD279 (Toripalimab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG4 kappa |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Toripalimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Toripalimab is a humanized monoclonal antibody that targets programmed death receptor 1 (PD-1). It is used to treat patients with unresectable or metastatic melanoma who have previously failed systemic therapy. It is intended for treatment Breast cancer, lymphoma, malignant melanoma, genitourinary system cancer and other types of solid tumors. |
Immunogen | n/a |
Other Names | Toripalimab, PDCD1/PD1/CD279, 1924598-82-2 |
Gene, Accession # | CAS: 1924598-82-2 |
Catalog # | abx831499 |
Price | please inquire |
Order / More Info | PDCD1/PD1/CD279 (Toripalimab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950